Literature DB >> 11755415

Host-Salmonella interaction: human trials.

M M Levine1, C O Tacket, M B Sztein.   

Abstract

Human clinical trials, including experimental challenges of volunteers with pathogenic Salmonella enterica serovar Typhi, small phase I and II trials that monitor the immune responses to vaccines, and large-scale controlled field trials that assess vaccine efficacy under conditions of natural challenge, have helped elucidate the interactions between Salmonella typhi and human hosts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11755415     DOI: 10.1016/s1286-4579(01)01487-3

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  40 in total

1.  Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects.

Authors:  David L Evers; Carol B Fowler; Jeffrey T Mason; Rebecca K Mimnall
Journal:  Sci Eng Ethics       Date:  2014-08-24       Impact factor: 3.525

2.  Characterization of anti-Salmonella enterica serotype Typhi antibody responses in bacteremic Bangladeshi patients by an immunoaffinity proteomics-based technology.

Authors:  Richelle C Charles; Alaullah Sheikh; Bryan Krastins; Jason B Harris; M Saruar Bhuiyan; Regina C LaRocque; Tanya Logvinenko; David A Sarracino; Indira T Kudva; Jana Eisenstein; Michael J Podolsky; Anuj Kalsy; W Abdullah Brooks; Albrecht Ludwig; Manohar John; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2010-06-23

3.  Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi.

Authors:  Janet C Lindow; Kelly A Fimlaid; Janice Y Bunn; Beth D Kirkpatrick
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

4.  Early eradication of persistent Salmonella infection primes antibody-mediated protective immunity to recurrent infection.

Authors:  Tanner M Johanns; Calvin Y Law; Lokeshchandra A Kalekar; Hope O'Donnell; James M Ertelt; Jared H Rowe; Sing Sing Way
Journal:  Microbes Infect       Date:  2010-12-04       Impact factor: 2.700

5.  Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans.

Authors:  R Wahid; R Salerno-Gonçalves; C O Tacket; M M Levine; M B Sztein
Journal:  Mucosal Immunol       Date:  2008-07-02       Impact factor: 7.313

6.  Transcriptional response in the peripheral blood of patients infected with Salmonella enterica serovar Typhi.

Authors:  Lucinda J Thompson; Sarah J Dunstan; Christiane Dolecek; Tim Perkins; Deborah House; Gordon Dougan; Thi Hue Nguyen; Thi Phi La Tran; Cong Du Doan; Thi Phuong Le; Thi Dung Nguyen; Tinh Hien Tran; Jeremy J Farrar; Denise Monack; David J Lynn; Stephen J Popper; Stanley Falkow
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

7.  Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal.

Authors:  Anoop S Pulickal; Samir Gautam; Elizabeth A Clutterbuck; Stephen Thorson; Buddha Basynat; Neelam Adhikari; Katherine Makepeace; Sjoerd Rijpkema; Ray Borrow; Jeremy J Farrar; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2009-08-26

8.  Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells.

Authors:  Irina Kochetkova; Theresa Trunkle; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

9.  Oral immunization with ATP-dependent protease-deficient mutants protects mice against subsequent oral challenge with virulent Salmonella enterica serovar typhimurium.

Authors:  Hidenori Matsui; Masato Suzuki; Yasunori Isshiki; Chie Kodama; Masahiro Eguchi; Yuji Kikuchi; Kenji Motokawa; Akiko Takaya; Toshifumi Tomoyasu; Tomoko Yamamoto
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.

Authors:  Hakim Echchannaoui; Matteo Bianchi; David Baud; Martine Bobst; Jean-Christophe Stehle; Denise Nardelli-Haefliger
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.